Literature DB >> 2916042

Spinal lesions: quantitative and qualitative temporal evolution of gadopentetate dimeglumine enhancement in MR imaging.

G Sze1, S Bravo, G Krol.   

Abstract

Seventy gadolinium-enhanced magnetic resonance imaging studies were reviewed, and 36 were selected for quantitative and qualitative analysis of the temporal evolution of contrast medium enhancement of spinal lesions. In the extradural space, lesions often showed mild increase of enhancement on delayed images, but enhancement was always visible on immediate postcontrast images. In the intradural extramedullary space, tumor nodules demonstrated most prominent enhancement on early images, although subtle, strandlike enhancement of the nerve roots showed some delayed uptake of contrast medium on later images. In the intramedullary space, enhancement often increased on delayed images, although this increase was usually mild. For clinical purposes, immediate postcontrast imaging should be sufficient to depict the majority of spinal lesions, regardless of location. However, selected cases, such as necrotic spinal cord tumors, will require delayed imaging.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2916042     DOI: 10.1148/radiology.170.3.2916042

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  4 in total

1.  New applications of MR contrast agents in neuroradiology.

Authors:  G Sze
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Comparison of plain and Gd-DTPA-enhanced MR-imaging in children.

Authors:  P Baierl; A Mühlsteffen; J Haustein; W M Bauer; C Förster; H Fendel; H P Niendorf
Journal:  Pediatr Radiol       Date:  1990

Review 3.  Magnetic resonance imaging of intramedullary spinal cord tumors.

Authors:  G M Lowe
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

4.  Spinal cord sarcoidosis.

Authors:  J Rieger; N Hosten
Journal:  Neuroradiology       Date:  1994-11       Impact factor: 2.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.